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Fig.l
HIV-1 Vector (RNL4·3~+cass)
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RETROVIRAL VECTOR AND CELL-BASED ASSAY
FOR MEASURING THE MUTATIONS RATE OF
RETROVIRUSES EMPLOYING SAME
[0001] The present invention is directed toward a cell
based assay that allows direct measurement of the mutation
rate of retroviruses during replication. The assay employs a
novellentivirus-based retroviral vector which is replication
defective but transduction and infection competent. More
particularly, the assay may be used to calculate the mutation
frequency and mutation rate of HIV-1.
[0002] Over twenty years into the ever-worsening AIDS
pandemic, genetic variation remains the greatest obstacle for
treating and preventing HIV-1 infection. To date, there are
no assays that directly measure the mutation rate of HIV-1
during replication in cell culture. There is an established
need in the art for a phenotypic cell-based test for directly
measuring the mutation rate of HIV-1.
[0003] A high degree of genetic variation is associated
with retroviruses in general and HIV-1 in particular, during
the course of infection. This variation enables the virus to
escape the host immune response, use multiple cell surface
proteins for viral entry, mount resistance to antiretroviral
drugs, and prevent effective vaccination. The polymerase
enzymes responsible for replicating the HIV-1 genome are
host cell DNA-dependent DNA polymerase, host cell RNA
polymerase II, and the virally-encoded reverse transcriptase
enzyme (RT). The host cell DNA-dependent DNA poly
merase replicates the integrated provirus during cellular
proliferation; it is not a mutation-prone polymerase and has
a negligible contribution to the high mutation rate during
HIV-1 replication. The host cell RNA polymerase II is
responsible for transcription of the integrated provirus. To
date, an accurate measurement of the RNA polymerase II
mutation rate has not been reported. However, evidence
suggests that RNA polymerase II has proofreading capabil
ity, diminishing its reputed role in HIV-1 mutation. Reverse
transcriptase (RT) copies the single-stranded RNA genome
into a double-stranded DNA molecule. The RT enzyme is
notoriously error-prone; its mutation rate is several orders of
magnitude higher than DNA polymerases, due mainly to the
lack of an associated 3'---;.5' exonuclease activity. Conse
quently, RT is considered to be the principal contributor to
HIV-1 genetic variation.
[0004]

Early in the AIDS epidemic, measurements of the
HIV-1 mutation rate were performed in cell-free studies
using artificial templates and purified enzyme and substrates
(hereafter referred to as in vitro studies). These in vitro
studies predicted the mutation rate for HIV-1 to be on the
order of 1o- 4 mutations per base per replication cycle. Other
in vitro studies followed these initial reports using various
assays to characterize the types of mutations such as base
substitutions, insertions, and deletions that are associated
with the high RT mutation rate. In vitro systems, however,
may not accurately duplicate the physiologic conditions of a
replicating virus. For example, retroviral mutations rates are
higher in vitro as compared to rates measured during repli
cation of the virus in cells (hereafter referred to as in vivo).
Other researchers have shown that in vitro systems can
generate reverse transcription products that are not naturally
found in vivo, such as extended minus-strand strong stop
DNA and non-templated base additions.
In 1995, Mansky and Temin, (J. Viral. 689:5087-94
(1995)), reported the development of an in vivo assay for

[0005]

measuring the mutation rate of HIV-1. The Mansky assay,
however, measures the mutation rate indirectly and has
several major drawbacks. The assay is indirect because it
does not detect mutant proviruses in the target cell. Instead,
the mutational target sequence, the lacZa peptide gene, is
excised from the provirus and introduced into a bacterial
system, where the mutational screening actually takes place.
The screening is based on visual blue/white color selection
of bacterial colonies on agar plates. This color selection is
not an all-or-none effect. That is, there are many interme
diate shades of blue, creating a subjective mutation detection
process. The lacZa peptide gene is isolated from a sea of
pooled target cell genomic DNA by binding to a Lac
repressor protein and recovery on nitrocellulose. This
method is very labor intensive. Furthermore, the Lac repres
sor protein is not readily available and typically must be
custom-made. The reference assay is also indirect because
colonies on the target cell dishes are pooled after the single
cycle of viral replication. This pooling step results in a
sampling type of measurement as opposed to a direct
measurement. There is no way to know whether mutants are
independent, potentially skewing the results on the types of
mutations observed in this system. Because the cells are
pooled, there is also no way to know the total number of
viruses screened or number of mutant viruses detected. The
lacZa peptide gene is small (280 bp) and the viral titers in the
reference assay are low. These two features decrease the
frequency by which mutants are detected and increase the
number of infections that must be performed, thus increas
ing cost. In fact, in order to achieve sufficient viral titers, the
reference assay relies on co-cultivation of mitomycin
treated virus-producing cells with target cells. Therefore, the
vast majority of viral infections are forced cell-to-cell as
opposed to infections by cell-free virus particles. The last
major drawback of this assay is that it has not been made
readily available to other researchers for independent veri
fication and scientific study.
[0006]

Hence, there is a need in the art for a more
economic, less-labor intensive, improved, readily available
and independent cell-based assay to directly and more
accurately measure the mutation rate of retroviruses, and, in
particular, HIV-1.
[0007]

Accordingly, embodiments ofthe present invention
are designed to provide a mutation rate assay that overcomes
one or more of the deficiencies discussed above.

[0008] In a broad vector embodiment, a lentivirus-based
retroviral vector is provided wherein the vector comprises:
at least a portion of a lentivirus genome; a disrupted gag and
a disrupted pol gene such that the vector is rendered repli
cation-defective; a disrupted env gene; and a mutational
cassette, wherein the mutational cassette comprises
sequences encoding: a mutation target promoter sequence; a
genomic source comprising a mutation target gene wherein
there is a number of base pairs in the mutation target gene;
an internal ribosome entry site for expression of a selectable
marker; and a selectable marker gene.
[0009]

In more specific embodiments, the lentivirus
genome is selected from a group of retroviruses including
human immunodeficiency virus type 1. In other specific
embodiments the selectable marker comprises a hygromycin
B resistance gene, the mutation target promoter comprises a
human cytomegalovirus promoter, the mutation target may
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comprise a thymidine kinase gene, and the genomic source
comprising a mutation target gene may comprise a human
herpes virus type 1 gene. Another aspect of the invention is
directed to a cell comprising the inventive lentivirus.
[0010] Another embodiment of the invention is directed to
an assay for determining mutation frequency and mutation
rate of a retrovirus. The assay comprises: a) constructing a
pertinent embodiment of the inventive vector; b) stably
transfecting cells from a cell culture with the vector from (a)
wherein the cell culture is negative for the mutation target
gene; c) placing the cells under selection with a medium
selectable for the selectable marker to produce a quantity of
cell clones which contain an integrated vector; d) transiently
transfecting the quantity of cell clones with a set of helper
plasmids to produce a vector virus, wherein the set of helper
plasmids contain a complement of structural genes which
permit replication; e) infecting naive cells from a cell culture
with the vector virus; f) placing the cells from (e) under
selection with the medium selectable for the selectable
marker; g) cloning the cells from (f) to produce a quantity of
initiator cell clones, wherein each of the quantity of cell
clones is designated as an Initiator Clone (I C); h) confirming
that the mutation target gene is functional in each IC and
sequencing the mutation target gene for later comparison to
mutation target genes which have undergone a cycle of
replication; i) transiently transfecting the ICs with a set of
helper plasmids to produce a vector virus; j) infecting naive
cells from a target cell culture with the vector virus from (i)
to produce a quantity of infected target cells; k) placing a
first portion of the quantity of infected target cells under
selection with the medium selectable for the selectable
marker, placing a substantially similar second portion of the
quantity of infected target cells under selection with the
medium selectable for the selectable marker plus a selective
medium for the mutation target gene; and I) determining a
viral titer for the first portion and a viral titer for the second
portion by counting drug-resistant quantities, wherein the
mutation frequency is calculated by dividing the viral titer of
the second portion by the viral titer of the first portion, and
the mutation rate is calculated by dividing the mutation
frequency by the number of base pairs in the mutation target
gene.
[0011] In specific embodiments the retrovirus is selected
from the group consisting of, inter alia, human immunode
ficiency virus type 1. In further specific embodiments the
selectable marker gene may comprise a hygromycin B
resistance gene, the medium selectable for the selectable
marker may comprise hygromycin B, the mutation target
gene may comprise thymine kinase, and the medium select
able for the mutation target gene may comprise bromode
oxyyuridine.
[0012] Embodiments of the novel assay have one or more
advantages and/or improvements over other known in vivo
mutation rate assays. It is easier, more economical, and
faster to perform. It provides a direct measurement of the
mutation rate during a single cycle of viral replication, a
known number of mutants detected, and a known number of
viruses screened. The inventive assay incorporates a larger
target sequence that yields higher mutation frequencies and
uses a natural viral infection process (as opposed to forced
cell-to-cell infection). The present assay also has the poten
tial for mechanization.

[0013] The present retroviral vector and assay are addi
tionally advantageous in the field of personalized medicine
because they provide the potential for individualized moni
toring of drug regimens in HIV-infected patients and for
monitoring the development of drug resistance in infected
individuals as well as across infected populations. The
resultant target cells containing mutant proviruses that sur
vive the drug selection process and may be propagated for
further analysis. The vector and assay may be employed to
study genetic variation of retroviruses including HIV-1.
[0014] Embodiments of the assay described herein are
useful for studying HIV-1 evolution with respect to drug and
vaccine development. In addition, embodiments of the assay
may provide a novel phenotypic test that can measure the
rate at which HIV-1 is mutating. Additional embodiments,
objects and advantages of the invention will become more
fully apparent in view of the following detailed description
an in conjunction with the accompanying drawings.
[0015] FIG. 1: depicts an HIV-1 vector and flow chart for
an embodiment of the inventive mutation assay. The HIV-1
vector, pNL4-3lHcass, is shown at the top. Step 1: The
vector is stably transfected into naive 143B cells. The cells
are placed under selection with hygromycin B (Hyg) and
cloned. Step 2: The 143B cell clones containing an inte
grated HIV-1 vector are transiently transfected with HIV-1
helper plasmids to produce vector virus. Step 3: Vector virus
is used to infect fresh 143B cells. The cells are placed under
selection with Hyg and cloned. Step 4: The 143B cell clones
containing an integrated HIV-1 vector are transiently trans
fected with HIV-1 helper plasmids to produce vector virus
(same as step 2 except cells are infected, not transfected).
Step 5: Vector virus is used to infect fresh 143B cells. Step
6: Parallel infections are placed under selection with Hyg
alone and Hyg plus BudR. Viral titers are calculated by
counting the number of drug resistant colonies. The forward
mutation frequency is calculated as shown. Cells are cloned
for further analysis.
[0016] FIG. 2: depicts an analysis of the Initiator Clones
(ICs). (A) Agarose gel showing PCR results performed on
genomic DNA ofiCs 1-6 and genomic DNA of 143B cells.
The 1.6 kb band is specific for the HIV-1 vector sequence
spanning CMV through TK. Lane M is a 1 kb marker. The
predicted 1.6 kb PCR product was detected in all ICs but not
in 143B genomic DNA, as expected. (B) Southern blot
analysis of ICs 1-5. Lane C represents the 143B genomic
DNA negative control. A high molecular weight marker was
included on the gel with sizes listed on the left side. Only
one band was detected for each IC, indicating one provirus
per cell. In addition, the bands for each IC were different
sizes, indicating that the ICs were independent cell clones.
[0017] FIG. 3: illustrates the mutation rate of HIV-1. The
mutation rate for HIV-1 was measured from three indepen
dent Initiator Cell clones (ICs ). The number of infections is
listed inside the colunm for each IC. The error bars represent
1 standard deviation from the mean.
[0018] The following definitions will be useful to under
stand the several embodiments of invention disclosed
herein.
[0019] "cis"-refers to the presence of genes on the same
chromosome, viral genome, or molecule; cis-acting-used
in reference to the controlling effect of a regulatory gene or
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element on a gene present on the same chromosome, viral
genome, or molecule. Promoters, which affect the synthesis
of downstream mRNA are cis-acting control elements.
[0020] Retrovirus-RNA viruses that utilize reverse tran
scriptase (RT) during their replication cycle. Retroviral
genomic RNA is converted into double-stranded DNA by
RT. The double-stranded DNA form of the virus is capable
of being integrated into the chromosome of the infected cell;
once integrated, it is referred to as a "provirus." The provirus
serves as a template for RNA polymerase II and directs the
expression of RNA molecules which encode the structural
proteins and enzymes needed to produce new viral particles.
At each end of the provirus are structures called "long
terminal repeats" or "LTRs". The LTR contains numerous
regulatory signals including a promoter.
[0021] Lentivirus-a genus in the Retroviridae family of
retroviruses that give rise to slowly developing disease.
Diseases caused by these viruses are characterized by a long
incubation period and protracted course. An important factor
in the disease caused by these viruses is the high mutability
of the viral genome, which, inter alia, results in the produc
tion of mutants capable of evading the host immune
response. Non-limiting examples employable in the present
invention include HIV-1, HIV-2, visna-maedi virus, which
causes encephalitis (visna) or pneumonia (maedi) in sheep,
the caprine arthritis-encephalitis virus, which causes
immune deficiency, arthritis, and encephalopathy in goats;
equine infectious anemia virus, which causes autoimmune
hemolytic anemia, and encephalopathy in horses; feline
immunodeficiency virus (FIV), which causes immune defi
ciency in cats; bovine immunodeficiency virus (BIV), which
causes lymphadenopathy, lymphocytosis, and possibly cen
tral nervous system infection in cattle; and simian immu
nodeficiency virus (SIV), which cause immune deficiency
and encephalopathy in sub-human primates.
[0022] HIV (human immunodeficiency virus; including
HIV-1, and HIV-2), the etiologic agent of the human
acquired immune deficiency syndrome (AIDS).
[0023] Gene-a DNA sequence that comprises control
and coding sequences necessary for the production of a
particular protein, polypeptide or precursor-any portion of
the coding sequence so long as the desired enzymatic
activity is retained. A unit of heredity.
[0024] Mutant-a gene or gene product which displays
modifications in sequence and or functional properties when
compared to the wild-type gene or gene product.
[0025] Replication defective-refers to a virus that is not
capable of a complete, effective replication cycle such that
infective virions are not produced.
[0026] Provirus-used in reference to a virus that is inte
grated into a host cell chromosome (or genome) and is
transmitted from one cell generation to the next without
causing lysis or destruction of the host cell.
[0027] Selectable marker-a gene which encodes a pro
tein with a function that allows for the identification of cells
that have been transfected or transformed with the marker
gene (for example, an enzyme that confers resistance to an
antibiotic or drug upon the cell in which the selectable
marker is expressed). A positive selective marker is a gene
whose expression permits the cell to live in the presence of

a selectable agent. The selectable agent is a compound that
distinguishes cells that do not express the selectable marker,
typically by killing them. Bacterial hygromycin B phospho
transferase (hyg) that confers resistance to the antibiotic
hygromycin B and the bacterial xanthine-guanine phospho
ribosyl transferase gene (also referred to a the gpt gene) that
confers the ability to grow in the presence of mycophenolic
acid are examples. Other selectable markers negative in that
their use kills cells that do express the protein encoded by
the selectable marker and their use is typically in conjunc
tion with a cell line that lacks the relevant activity. Examples
of negative selectable markers include the thymidine kinase
(tk) gene that is used in conjunction with TK-negative cells.
It is understood that TK-negative means that the cell does
not express a functional TK protein and does not necessarily
mean an absolute absence. A person skilled in the art will
appreciate that there are many manipulations and disable
ments that may be undertaken to eliminate the expression of
a functional form of the typically expressed protein.
[0028] Vector-nucleic acid molecules that transfer
nucleic acid segments from one cell to another. It is intended
that any form of a vector may be encompassed by this
definition. For example, vectors include but are not limited
to: viral vectors; plasmids; transposons; and so on.
[0029] Cassette-a fragment or segment of DNA contain
ing a particular grouping of genetic elements and/or genes.
A cassette can be removed and inserted into a vector or
plasmid as a single functional unit.
[0030] Transfection-the uptake, expression and/or incor
poration of foreign DNA into eukaryotic cells. May be
accomplished by a variety of means known or yet to be
developed in the art.
[0031] Transduction-refers to the delivery of genetic
material using a viral or retroviral vector by means of
infection rather than by transfection. In specific embodi
ments, retroviral vectors are used to transduce eukaryotic
cells. E.g. a gene carried by a retroviral vector can be
transduced into a cell through infection and provirus inte
gration. A transduced gene is one that has been introduced
into the cell via lentiviral or vector virus infection and
provirus integration.
[0032] Stably transduced-refers to the introduction and
integration of foreign DNA into the genome of the trans
ducted cell. "Stable transductant" refers to a cell which has
stably integrated foreign DNA into the genomic DNA.
[0033] Transiently transduced-introduction of foreign
DNA into a cell where the foreign DNA fails to integrate into
the genome of the transducted cell. The foreign DNA may
persist in the nucleus ofthe transducted cell for several days.
During this time the foreign DNA is subject to the regulatory
controls that govern the expression of endogenous genes in
the chromosomes.
[0034] Non-dividing cell-target and/or host cells that do
not divide, e.g. neuronal cells. Embodiments of the present
assay are not intended to be limited to non-dividing cells.
[0035] Embodiments of the present inventive lentiviral
based retrovirus vector and cell-based assay for measuring
the mutation rate of retroviruses are described in detail
below.
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[0036] The inventive assay as exemplified herein will
yield conservative measurements for mutation rates. First,
the entire tk sequence (996 bp) is used in the calculation.
Second, some mutant proviruses will have more than one
mutation. Although every base in the tk gene is subject to a
potential deletion or insertion, not every base is subject to a
non-synonymous base change. For tk, the probability of
whether a base substitution will result in an amino acid
replacement is 74%. That is, if random mutations occurred
throughout the gene, 737 out of the 996 base changes would
result in an amino acid change, but not all amino acid
substitutions would result in loss of function for TK. Amino
acid substitutions that do not knock out TK function would
be susceptible to selection by BudR and would not be
detected in the assay. The inventors are not aware of any
reports on saturation mutagenesis of tk. Therefore, a com
prehensive catalog of inactivating tk mutations is not avail
able. If the mutation rate in this study had been calculated
using 737 instead of 996 bases for tk, then the mutation rate
would be 3.0x10- 5 /base/cycle. The decision to include all
996 bases in the calculation considers all types ofmutations:
deletions, insertions, and substitutions. Mutant proviruses
were counted as one in the mutation rate calculation, even
though some mutants contained multiple genetic alterations.
Table 2, below, shows that there were 43 mutations among
27 mutants screened. If the mutation rate was adjusted to
account, for multiple mutations, then the rate would be
3.5x10 mutations/base/cycle. Thus, as stated, the reported
mutation rate is a conservative one and could be as much as
1.6-fold higher.
[0037] One embodiment ofthe inventive vector is directed
to a lentivirus-based retroviral vector wherein the vector
comprises: at least a portion of a lentivirus genome; a
disrupted gag and a disrupted pol gene such that the vector
is rendered replication-defective; a disrupted env gene; and
a mutational cassette, wherein the mutational cassette com
prises sequences encoding: a mutation target promoter
sequence; a genomic source comprising a mutation target
gene wherein there is a number of base pairs in the mutation
target gene; an internal ribosome entry site for expression of
a selectable marker gene; and a selectable marker gene.
[0038] Retroviruses are a class of viruses that have a
single stranded, positive sense RNA genome and replicate
through a double-stranded DNA intermediate directed by the
process ofreverse transcription (RT). The DNA intermediate
is referred to as the provirus. The provirus integrates into the
host cell genome, thereby becoming acquired genetic mate
rial. HIV-1 is a lentivirus, which is a genus of retroviruses.
Lentiviruses are unique retroviruses that possess the ability
to replicate in quiescent cells as well as replicating cells.
Lentiviruses are associated with immune deficiency and
neurodegeneration of the host. Examples of other lentivi
ruses include simian immunodeficiency virus (SIV), bovine
immunodeficiency virus (BIV), and feline immunodefi
ciency virus (FIV).
[0039] A gene is "disrupted" if it is rendered incapable of
expressing its functional polypeptide. It may be disrupted by
completely deleting it or by removing its initiation codon,
inserting stop codons or base pairs to force a frameshift. One
skilled in the art will appreciate that there are many effective
means to disrupt a gene. In a specific embodiment the vector
is replication deficient but transduction- and infection-com
petent.

[0040] In another specific embodiment the lentivirus
genome is selected from the group consisting of human
immunodeficiency virus type 1 (HIV-1 ), human immunode
ficiency virus type 2, feline immunodeficiency virus, simian
immunodeficiency virus, visna-maedi virus, caprine arthri
tis-encephalitis virus, equine infectious anemia virus, and
bovine immunodeficiency virus. In a very specific embodi
ment the lentivirus genome comprises HIV-1. In certain
embodiments the genome may comprise a hybrid of the
aforementioned lentivirus genomes.
[0041] In one aspect of the retrovirus vector the selectable
marker comprises a positive selectable marker. In a further
aspect the selectable marker comprises an antibiotic or drug
resistance gene. In a very specific aspect, the internal ribo
somal entry site promotes translation of the selectable
marker and the selectable marker comprises a hygromycin B
resistance gene. One skilled in the art will appreciate that the
choice of promoter depends upon which drug resistance
gene is employed as the selectable marker and that many
means are commonly known in the art that suggest or
determine an appropriate selection.
[0042] In specific embodiments the number of base pairs
in the mutation target gene is greater than 300 base pairs. A
greater number of base pairs increases the size of the
mutational target and, therefore, increases the statistical
reliability and validity of the results. In more specific
embodiments the number of base pairs in the mutation target
gene is greater than 500 base pairs, and in a very specific
embodiment the number of base pairs in the mutation target
gene is greater than 700 base pairs. In a particular embodi
ment the mutation target comprises a thymidine kinase gene
that comprises about 1000 base pairs. In one embodiment
the genomic source comprising a mutation target gene
comprises a human herpes virus type 1 gene.
[0043] Promoters are used to enhance or increase the
expression of genes in the retrovirus vector. A promoter is a
regulatory element that facilitates the initiation of transcrip
tion of an operably linked coding region. The selection of a
particular promoter depends on what cell type is to be used
to express a protein, polypeptide or enzyme of interest. In
one particular embodiment the mutation target promoter
comprises a human cytomegalovirus (CMV) promoter and
the mutation target comprises a thymidine kinase (tk) gene.
[0044] Another embodiment of the invention is directed to
a cell comprising the present lentivirus-based retroviral
vector. The cell may comprise any cell which the vector is
capable of infecting. Generally speaking, it will be a eukary
otic cell, preferably a vertebrate cell, more preferably a cell
of a mammal. The cell may be a dividing or non-dividing
cell. Non-limiting examples of non-dividing cells include
neuronal cells and astrocytes. Non-limiting examples of
dividing cells include hematopoietic stem cells, muscle
cells, white blood cells, spleen cells, liver cells, epithelial
cells and eye cells. In one embodiment the cell of interest is
negative for the mutation target gene. It is appreciated by
those skilled in the art that "negative" in this context does
not necessarily mean it is not present, but that it is disabled
or disrupted to a degree that prevents the expression of a
functional expression product. The inventors contemplate
that expression product functioning may even be suppressed
by an agent such as a drug or other compound. In a particular
embodiment where the mutation target gene is thymidine
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kinase, the cells comprise 143B cells. In one particul~r
embodiment the cell is a dividing or non-dividing eukaryot1c
cell.
[0045] Another embodiment of the present invention pro
vides an assay for determining a mutation frequency and a
mutation rate of a retrovirus. The assay comprises: a)
constructing the vector described above; b) stably transfect
ing cells from a cell culture with the vector from (a) wherein
the cell culture is negative for the mutation target gene; c)
placing the cells under selection with a medium selectable
for the selectable marker to produce a quantity of cell clones
which contain an integrated vector; d) transiently transfect
ing the quantity of cell clones with a set of helper plasmids
to produce a vector virus, wherein the set of helper plasmids
contain a complement of structural genes which permit
replication; e) infecting naive cells from a cell culture ":ith
the vector virus; f) placing the cells from (e) under selection
with the medium selectable for the selectable marker; g)
cloning the cells from (f) to produce a quantity of cell clones,
wherein each of the quantity of cell clones is designated as
an Initiator Clone; h) confirming that the mutation target
gene is functional in each Initiator Clone (IC) and, option
ally, sequencing the mutation target gene for later compari
son to mutation target genes which have undergone a cycle
of replication; i) transiently transfecting the ICs with a set of
helper plasmids to produce a vector virus; j) infecting naive
cells from a target cell culture with the vector virus from (i)
to produce a quantity of infected target cells; k) placing a
first portion of the quantity of infected target cells under
selection with the medium selectable for the selectable
marker and a substantially similar second portion of the
quantity of infected target cells under selection with the
medium selectable for the selectable marker plus a selective
medium for the mutation target gene; and I) determining a
viral titer for the first portion and a viral titer for the second
portion by counting drug-resistant quantities, wherein the
mutation frequency is calculated by dividing the viral titer of
the second portion by the viral titer of the first portion, and
the mutation rate is calculated by dividing the mutation
frequency by the number of base pairs in the mutation ta:get
gene. In one embodiment, the assay further compnses
providing a negative control group, wherein a quantity of
naive cells from the cell culture is left uninfected and placed
under selection with the medium selectable for the selectable
marker plus a medium selectable for the mutation target
gene.
[0046] In more specific embodiments the retrovirus is
selected from the group consisting of human immunodefi
ciency virus type 1, human immunodeficiency virus type 2,
feline immunodeficiency virus, simian immunodeficiency
virus, visna-maedi virus, caprine arthritis-encephalitis virus,
equine infectious anemia virus, and bovine immunodefi
ciency virus. In a very specific embodiment the retrovirus is
human immunodeficiency virus type 1.
[0047] In further specific embodiments the selectable
marker gene comprises an antibiotic or drug resistance gene
and the medium selectable for the selectable marker com
prises the corresponding antibiotic or drug. In one aspect the
selectable marker gene comprises a hygromycin B resistance
gene and the medium selectable for the selectable marker
comprises hygromycin B.
[0048] In additional embodiments the mutation target
gene is a thymine kinase gene and the medium selectable for

the mutation target gene comprises bromodeoxyuridine,
gancyclivir, acyclivir, or HAT (hypoxanthine+aminopterin+
thymine). In a very specific embodiment the medium select
able for the mutation target gene comprises bromodeoxyuri
dine.
[0049] In one aspect the cell culture comprises 143B cells.
The 143B cell culture is a cell line available from the
American Type Culture Collection, Manassas, Va. This cell
line is a derivative of the human osteosarcoma cell line,
HOS, and is negative for thymidine kinase (TK) function.
[0050] The following descriptions and examples of the
various embodiments of the invention have been presented
for the purposes of illustration and are not intended to be
exhaustive or to limit the invention to the precise form
disclosed. Many alternatives, modifications and variations
will be apparent to those skilled in the art. Accordingly, this
invention is intended to embrace all alternatives, modifica
tions and variations that are discussed and exemplified
herein, and others that fall within the spirit and broad scope
of the claims.

EXAMPLES
[0051] With respect to all the examples disclosed herein,
the full-length HIV-1 genome that served as the basis for the
HIV-1 vector (FIG. 1, top) and the p83-10 plasmid that
contains the 3' half of HIV-1 NL4 _3 were obtained through the
AIDS Research and Reference Reagent Program, Division
of AIDS, NIAID, NIH: pNL4-3. The helper plasmids,
pCMVllR8.2 and pMD.G, were generously provided from
the University of Geneva, Switzerland. Plasmid pCM
VAR8.2 encodes structural proteins Gag and Pol, in addition
to all of the HIV-1 accessory proteins. This Gag-Pol helper
expresses sequences derived from both the HXB2J? and
NILA-3 strains of HIV-1. However, the reverse transcnptase
portion of pCMVllR8.2 was derived completely from
NL4-3 (accession no. M19921 ). The pMD.G helper plasmid
expresses G glycoprotein of vesicular stomatitis virus
(VSV.G) and confers broad tropism via pseudotyping of the
HIV-1 vector virus. Both of the helper plasmids express
genes from heterologous promoters. The piREShyg2 plas
mid was purchased from Clontech, a division of BD Bio
sciences, Palo Alto, Calif. The gene for thymidine kinase
(tk) was cloned from plasmid pKOS 17B2, obtained from
Harvard Medical School, Boston, Mass.
[0052] General molecular biology procedures, includiJ_Ig
restriction enzyme digestion, agarose gel electrophoresis,
DNA ligation, and bacterial transformation were performed
using standard published procedures (see Ausubel et a!.
"Current Protocols in Molecular Biology, John Wiley &
Sons (1995) and Sambrook et a!. "Molecular Cloning: a
laboratory manual" Cold Spring Harbor Laboratory, NY,
(1989), incorporated herein by reference).
[0053] All enzymes were purchased from New England
Biolabs, Inc., Beverly, Mass., unless otherwise noted.

Example 1
[0054] This example illustrates the difference in the muta
tion rate derived from employment of an embodiment of the
inventive assay wherein HIV-1 is the retrovirus measured,
and that derived from the reference Mansky in vivo assay on
HIV-1.
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[0055] The average mutation rate derived from the present
assay is 1.6-fold lower than the rate reported by Mansky and
Temin (1995) using the indirect in vivo assay for HIV-1
(Table 3). Mansky's average rate was 3.5x1o-s mutations/
base/cycle. As shown in Table 3, Mansky's rate was based
on lower numbers of mutants detected (specifically, 9.2-fold
lower). Most likely, the lower frequency was due to the
difference in the sizes ofthe mutational target sequences; the
Mansky assay uses the lacZa peptide sequence, which is 3.6
times smaller than the tk sequence used in the practice ofthis
embodiment of the invention. The number of viruses
screened cannot be directly compared because this number
is unknown for the Mansky assay. A total number of 15,930
viruses were screened in this example, while a total number
of 8,678 bacterial colonies were screened in the Mansky
assay. It is unlikely that each bacterial colony in the Mansky
assay corresponds to an independent proviral sequence
because cell colonies, each containing numerous cells, were
pooled in the final step.
[0056] This last point may explain why differences were
found in the types of mutations observed in the present
example versus Mansky assays (Table 2). In both assays, the
majority of mutations were base substitutions. However,
there were significantly less G---;.A transitions observed in
the present example as compared to the Mansky assay
(p=0.04). There were significantly more insertions observed
in the present example as compared to the Mansky assay
(p=0.02). There were significantly less single nucleotide
deletions observed in the present example as compared to
the Mansky assay (p=0.02). Lastly, there were significantly
less transition mutations, and conversely more transversion
mutations, observed in the present assay as compared to the
Mansky assay (p=0.01). Frequencies were used in a one
tailed Fisher's exact test to determine the statistical signifi
cance with an alpha level of 0.05. For some categories of
mutants, the numbers were too small for statistical analyses.

Example 2
[0057] This example illustrates construction of an HIV-1
vector, named pNL4-3lHcass.
[0058] A replication-defective HIV-1 vector was con
structed based on the NL4-3 strain of HIV-1 (FIG. 1, top).
The vector contains all of the cis-acting sequences necessary
for replication, plus a complete set of intact accessory genes
for HIV-1. Deletions were made in the gag, pol, and env
genes to render the vector replication defective. Structural
gene products, Gag, Pol, and Env, were supplied in trans by
helper plasmids. In place of env, a mutational cassette was
inserted that contained the human CMV promoter driving
expression of tk, which provided the mutational target
sequence for the assay. A functional tk gene renders cells
resistant to medium containing HAT and susceptible to
medium containing BrdU. An IRES sequence following tk
allowed for expression of hyg, which provided a selectable
marker via resistance to the antibiotic hygromycin B.
[0059] The final HIV-1 vector, named pNL4-3lHcass, was
verified by restriction enzyme analysis, sequencing, and
phenotypic testing in 143B cells. All plasmid constructs
leading up to the final vector were digested with restriction
enzymes to verify the cloning process. The final vector was
digested with six restriction enzymes (Aft II, Hind III, Kpn
I, Pst I, Sac I, and Xnm I) and showed only bands of the

predicted sizes, indicating that no major rearrangements,
insertions, or deletions had occurred during the cloning
process (data not shown). Sequencing revealed that the tk
gene had no mutational defects. The final vector was trans
fected into naive 143B cells, which are negative for TK
function. The transfected cells were resistant to medium
containing HAT and susceptible to medium containing
BrdU, indicating that tk was functional. The transfected cells
were also resistant to medium containing hygromycin B,
indicating that hyg was functional. Finally, transfection of
naive 143B cells with pNL4-3lHcass plus helper plasmids
yielded virus, as indicated by successful transduction of the
tk and hyg genes into fresh 143B cells.
[0060] To create the pNL4-3lHcass vector (FIG. 1, top),
deletions were made in the gag, pol, and env genes of
pNL4-3, and a mutational cassette was inserted at the
location of the env deletion. The deletion in gag-pol (cor
responding to nucleotides 1340-3716 of the original NL4-3
sequence, accession no. M19921) was created by digesting
pNL4-3 with Swa I and purifYing the 12,503 bp fragment,
which contained the plasmid backbone and the gag-pol
deleted HIV-1 genome. The fragment was isolated using the
Qiaquick Gel Extraction Kit (Qiagen, Valencia, Calif.) and
ligated with T 4 DNA ligase. This intermediate construct was
named pNL4-3llswa.
[0061] The deletion in env (corresponding to nucleotides
6401-7252 of the original NL4-3 sequence, accession no.
M19921) was created in p83-1 0 (6,253 bp ), which contains
the 3' half of the HIV-1 genome. Working with the 3' half of
the HIV-1 genome allowed the use of restriction enzymes
that were not unique in the full-length pNL4-3 plasmid.
Plasmid p83-10 was digested with Nde I and Nhe I; the
5,402 bp fragment, which contained the plasmid backbone
and the env-deleted 3' half of HIV-1, was isolated by using
the Qiaquick Gel Extraction Kit (Qiagen). This fragment
was ligated with complementary oligonucleotides that
inserted a multiple cloning site (MCS), creating intermediate
construct p83-10MCS. The sequences of the oligonucle
otides are as follows: MCS1 5'-TAT GGG CGC GCC ACG
CGT CCC GGG G-3' and MCS2 5'-GCT AGC CCC GGG
ACG CGT GGC GCG CCC ATA TG-3'. Restriction
enzymes Sal I and Xho I were used to isolate a fragment
from p83-10MCS that contained the env deletion. This
fragment was then used to replace the corresponding frag
ment in pNL4-3llswa that contained the intact env sequence.
These cloning steps created intermediate construct pNL4
3ll.
[0062] The mutational cassette was created by using
piREShyg2 from Clontech. The piREShyg2 plasmid is a
bi-cistronic expression vector that expresses a gene of
interest (tk, in this case) from the human cytomegalovirus
(CMV) promoter. An internal ribosome entry site (IRES)
allows for expression of the second gene, hygromycin
phosphotransferase (hyg), which provided a selectable
marker via resistance to the antibiotic hygromycin B. The tk
sequence was amplified by polymerase chain reaction (PCR)
from plasmid pKOS 17B2 using a set of primers containing
BsrG I and BsiWI sites at 5' and 3' ends, respectively; tk was
inserted into the MCS of piREShyg2 using these sites after
intermediary cloning in a TOPO TA vector (Invitrogen,
Carlsbad,
Calif.),
creating intermediate construct
pTKIREShyg. The sequence encompassing the CMV pro
moter, tk, IRES, and hyg was then amplified from

US 2007/0042352 AI

Feb.22,2007
7

pTKIREShyg using a set of primers containing Mlu I and
Nhe I sites at 5' and 3' ends, respectively. Following inter
mediary cloning in a TOPO TA vector, these restriction sites
were used to insert the CMV-tk-IRES-hyg mutational cas
sette into pNL4-3ll. to create the final vector, pNL4-3ll.+cass.
[0063] For cloning into the mutational cassette, the tk gene
was amplified using Taq DNA polymerase in a 100-f.ll
reaction, according to the manufacturer's protocol (Invitro
gen). Twenty-five nanograms of plasmid pKOS17B2 was
used in the reaction, along with 20 pmol of each of the
following primers: TK1 5'-GCT ATG TAC AGC CAC CAT
GCC CAC GCT ACT GCG GGT-3' and TK2 5'-GTA CCG
TAC GTC AGT TAG CCT CCC CCA TCT-3'. The TK1
primer encodes a BsrG I site near the 5' end followed by a
Kozak sequence. The TK2 primer encodes the 3' end of tk,
followed by a BsiWI site. Twenty-five cycles of the follow
ing program were performed: 15 sec. at 94° C., 15 sec. at 60°
C., and 1 min. at no C. Taq DNA polymerase was added to
the reaction after an initial heating step at 94 o C. for 5 min,
and a final extension step was performed at 72° C. for 10
mm.
[0064] For cloning into the HIV-1 vector, the CMV-tk
IRES-tyg mutational cassette was amplified using Pfu
Turbo® polymerase (Stratagene, La Jolla, Calif.) in a 50-f.ll
reaction, according to the manufacturer's protocol. Twenty
five nanograms of plasmid pTKIREShyg were used in the
reaction, along with 10 pmol of each of the following
primers: CMVCAS 1 5'-GAT CAC GCG TCG CGT TAC
ATA ACT TAC GGT A-3' and CMVCAS 2 5'-GTC AGC
TAG CTT CCT TTG CCC TCG GAC GAG-3'. CMVCAS
1 encodes an Mlu I restriction enzyme site prior to the CMV
promoter sequence, and CMVCAS 2 encodes the 3' end of
hyg, followed by a Nhe I restriction enzyme site. Twenty
five cycles of the following program were performed: 1 min.
at 95° C., 1 min. at 58° C., and 4 min. at no C. An initial
heating step at 95° C. for 3 min. and a final extension step
at no C. for 10 min. were performed.
Example 3
[0065] The following example illustrates utilization of one
embodiment of the assay to determine the mutation rate of
HV-1.
[0066] The mutation rate assay for this example is outlined
in FIG. 1. Serial dilutions of HIV-1 vector DNA were
transfected into 143B cells, which were placed in medium
containing hygromycin B to select for resistant cells. Hygro
mycin B resistant cells were cloned by picking well-isolated
colonies from plates receiving the highest dilutions of DNA
(step 1, FIG. 1). In order to remove mutations that may have
occurred during transfection and to improve the probability
for isolating clones that contained only one vector per cell,
a subsequent infection step was performed. The 143B clones
containing the HIV-1 vector were transiently transfected
with HIV-1 helper plasmids for transient production of
vector virus (step 2, FIG. 1). Serial dilutions of this virus
were then used to infect fresh 143B cells, which were placed
in medium containing hygromycin B to select for resistant
cells. Hygromycin B-resistant cells were cloned by picking
well-isolated colonies from plates receiving the highest
dilutions of virus (step 3, FIG. 1). The resulting cell clones
were called the Initiator Cells (ICs) and served as the basis
for the single cycle of replication assay.

[0067] The ICs generated in step 3, FIG. 1, were rigor
ously characterized by molecular and phenotypic analyses to
ensure a successful and accurate mutation rate assay. Poly
merase chain reaction was performed with the genomic
DNA of each IC to detect the presence of provirus using
primers specific for the sequence that spans CMV through
tk. The same PCR was performed with the genomic DNA of
naive 143B cells as a negative control. The predicted PCR
product of 1,600 bp in length was detected in all ICs and not
in the naive 143B cells (FIG. 2A). A Southern blot analysis
was performed on the genomic DNA of each IC to ensure
that each IC contained only one HIV-1 vector sequence. The
cellular DNA was digested with EcoR I, which generated a
3' fragment of the viral genome with adjacent cellular DNA.
A radio labeled probe specific for this 3' region of the virus
was used to detect a single band in each IC (FIG. 2B). The
bands for each IC were different sizes, confirming that each
IC was an independent cell clone (FIG. 2B). Each IC was
grown in medium containing BrdU for a two-week period.
The BrdU selection resulted in the complete death of ICs 2,
3, and 4, indicating functional tk expression in these cell
clones. These ICs were chosen for the assay and their tk
genes were sequenced and found to be identical to the tk
sequence from the original pNL4-3ll.+cass vector. Transient
transfection of helper plasmids into the ICs produced viral
titers in the range of 102 to 104 cfu/ml, which provided a
sufficient number of mutants from a practical number of
infections.
[0068] Once the ICs were established, they were tran
siently transfected with the HIV-1 helper plasmids to gen
erate virus for the single cycle ofreplication (step 4, 628FIG.
1). HIV-1 vector virus was harvested from the ICs and used
to infect fresh 143B cells (step 5, FIG. 1). Steps 4 and 5
constitute the single cycle of replication (from provirus to
provirus, IC to target cell). Finally, parallel sets of infections
were placed under two types of drug selection: hygromycin
B plus BrdU (Hyg+BrdU) and hygromycin B alone (Hyg)
(step 6, FIG. 1). Mock infections, performed in parallel as a
negative control, showed no colony formation under the
Hyg+BrdU selection. Viral titers were determined by count
ing the number of drug-resistant colonies in the linear range
of the titration. The Hyg+BrdU titer revealed the number of
mutants, while the Hyg titer revealed the number of viruses
screened. The mutation frequency was calculated by divid
ing the total number of mutants detected by the total number
of viruses screened (final step, FIG. 1 and Table 1).
[0069] For verification of the Initiator Clones, the CMV-tk
region (1,600 bp) was amplified from genomic DNA (from
step 3, FIG. 1) using Taq DNA polymerase (Invitrogen) in
a 100-f.ll reaction, according to the manufacturer's protocol.
Two hundred nanograms of genomic DNA were used in the
reaction, along with 20 pmol of primers CMVCAS 1 and
TK2. Twenty-five cycles of the following program were
performed: 30 sec. at 94° C., 30 sec. at 58° C., and 2 min.
at no C. Taq DNA polymerase was added to the reaction
after an initial heating step at 94 o C. for 5 min, and a final
extension step was performed at 72° C. for 10 min.
[0070] The DNeasy Tissue Kit (Qiagen) was used to
isolate the genomic DNA from cultured cells per manufac
turer's protocol.
[0071] The 143B cell line was purchased from the Ameri
can Type Culture Collection, Manassas, Va. This cell line is
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a derivative of the human osteosarcoma cell line, HOS, and
is negative for thymidine kinase (TK) function. The cells
were maintained in minimal essential medium (MEM) with
Earl's BSS (Mediumtech, Herndon, Va.) supplemented with
10% fetal bovine serum, 2 mM L-glutamine, 100 U/ml
penicillin, 100 f.tg/ml streptomycin (Invitrogen). Cells were
passaged twice per week and were grown at 37° C. and 5%
C0 2 .
[0072] For selection of drug resistant colonies, cells were
cultured for two weeks in medium containing the appropri
ate agent. The final concentration for each agent was deter
mined empirically using 143B cells. The antibiotic hygro
mycin B (Invitrogen) was used at 0.27 mg/ml. The
nucleoside analog bromodeoxyuridine (BrdU; Sigma-Ald
rich Co., St. Louis, Mo.) was used at 0.12 mg/ml. The final
concentrations of hypoxanthine, aminopterin, and thymine
(HATi; Sigma-Aldrich) were 5x10- 5 M, 2x10- 7 M, and
8x10 M, respectively.
[0073] Cells were cloned by choosing well-isolated colo
nies from plates receiving the highest dilutions of DNA or
virus (steps 1 and 3, respectively, FIG. 1) or plates in the
linear range of the titration (step 6, FIG. 1). A sterile 5-mm
Bel-Art cloning disk (Fisher Scientific, Pittsburgh, Pa.)
treated with trypsin-EDTA (0.25%, Invitrogen) was placed
onto the colony, incubated for 3'h min., and transferred into
the well of a 24-well plate containing medium.
[0074] Stable and transient transfections (steps 1 and 2,
FIG. 1) were performed by the dimethyl sulfoxide (DMSO)/
polybrene method. For step 1, serial 5-fold dilutions of
DNA, starting with 5 flg, were transfected onto 143B cells
plated at 2x10 5 cells/60 mm dish 24 hours pre-infection. For
step 2, 9 flg of pCMVllR8.2 and 3 flg of pMD.G were
transfected onto cell clones (isolated from step 1) plated at
2x10 5 cells/60-mm dish, 24 hours pre-transfetion. After 6
hours of incubation with DNA, cells were shocked with 25%
DMSO for 3'h min. and were placed in appropriate selective
medium at 24 hours post-transfection.
[0075] Transient transfection (step 4, FIG. 1) was per
formed using the LipofectAMINE™ 2000 per manufactur
er's protocol (Invitrogen). Three micrograms of
pCMVllR8.2 and one microgram of pMD.G were trans
fected onto ICs (isolated from step 3) plated at 2x10 5
cells/60-mm dish, 24 hours pre-transfection. The medium
was replaced 24 hours after transfection.
[0076] Virus stock was harvested at 62 hours post-trans
fection by centrifugation of cell supernatant fluid at 1430xg
for 10 min. at room temperature in sealed GH 3.8 rotor
buckets of a Beckman GS-6R tabletop centrifuge to remove
any detached cells. The 62-hour time point was chosen
empirically based on transduction efficiencies with the
HIV-1 based vector pHR'CMV-GFP, which encodes the
gene for green fluorescent protein, and helper plasmids
pCMVllR8.2 and pMD.G.
[0077] Infections were performed with fresh virus stock
and polybrene (8 flg/ml) in a final volume of 2 ml with cells
plated 24 hours pre-infection at a density of 2x1 0 5 cells/60
mm dish. Cells were incubated with virus for 3 hours, at
which time the viral supernatant was replaced with fresh
medium. At 24 hours post-infection, the medium was
replaced with fresh medium containing the appropriate
selective agent. Media containing the appropriate selective
agents were replaced twice a week for two weeks. Serial
10-fold dilutions of virus were used to determine viral titers,
which were measured by counting the number of drug-

resistant colonies in the linear range of the titration. Viral
titers are reported as the number of colony forming units per
milliliter (cfu/ml).
[0078] Mutation frequencies and rates were calculated
using simple mathematical formulas. The mutation fre
quency was calculated by dividing the total number of
mutants by the total number of viruses (Hyg+BrdU titer/Hyg
titer; FIG. 1 and Table 1). The mutation rate was calculated
by dividing the mutation frequency by the number of bases
in tk (996 bases).

Example 4
[0079] This example illustrates determination of mutation
types in the mutational target gene subsequent to the assay.
[0080] For sequencing of the final mutants, the tk gene
was amplified from genomic DNA isolated from the Target
Cells (final step, FIG. 1) using Accuprime™ Taq DNA
polymerase (Invitrogen) in a 10-f.ll reaction, according to the
manufacturer's protocol. Three hundred nanograms of
genomic DNA were used in the reaction, along with 20 pmol
of each of the following primers: TKA1 5'-TCA CTA TAG
GGA GAC CCA AGC 3' and TKA2 5'-CCC TCG CAG
ACA GCG AAT TAA-3'. Twenty-five cycles of the follow
ing program were performed: 45 sec. at 94 o C., 45 sec. at 58°
C., and 1 min. at no C. An initial heating step at 94° C. for
2 min. and a final extension step at no C. for 10 min. were
performed. Primers and excess nucleotides were inactivated
by adding 1.9 U Exonuclease I and 0.38 U Shrimp Alkaline
Phosphatase (Amersham Biosciences, Piscataway, N.J.) to
the PCR reaction. The final reaction volume was adjusted to
12.5 fll using ultra pure water. The reaction was incubated at
37° C. for 30 min., and enzymes were heat inactivated at 80°
C. for 20 min.
[0081] All PCR reactions were performed on a Peltier
Thermal Cycler 200 (MJ Research, Reno, Nev.) with the
exception of the final amplification of tk from the Target
Cells, which was performed on a GeneAmp PCR System
9600 (Applied Biosystems, Foster City, Calif.).
[0082] Southern blotting was performed using standard
published procedures (Ausubel and Sambrook, supra).
Briefly, 15 flg of genomic DNA was digested with EcoR I
and separated in a 1% agarose gel. DNA was transferred via
capillary action onto a Hybond-N+ membrane (Amersham).
The membrane was hybridized with a radiolabeled fragment
complementary to the 3' half of the HIV-1 genome (a 422-bp
BamH I to Xho I fragment, specific for the Rev-responsive
element and tat gene). The fragment was labeled using the
Rediprime™ II DNA Labeling System and a- 32 P dCTP per
manufacturer's protocol (Amersham). The Qiaquick Nucle
otide Removal Kit (Qiagen) was used to remove the excess
dNTPs from the radio labeled probe. The radioactive content
of the probe was quantified using a scintillation analyzer.
Results were visualized by autoradiography using Kodak
X-OMAT AR2 film (Fisher Scientific).
[0083] Purified PCR products were reduced to a concen
tration of 50 ng/fll by centrifugation under vacuum, and 200
ng of each sample was sent to Lark Technologies, Inc.,
Houston, Tex. for sequencing. The following two primers
were used: FORWARD-TK 5'-TAC CTT ATG GGC AGC
ATG ACC-3' and REVERSE-TK 5'-CTG CAG ATA CCG
CAC CGT ATT-3'. The sequencing results were aligned and
analyzed for non-synonymous base substitutions, insertions,
and deletions using MacVector™ software version 6.5.3
(Accelrys, San Diego, Calif.).
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Example 5
TABLE 1

[0084] This example compares the mutation rates calcu
lated according to an embodiment of the present assay with
calculations reported for a widely known assay that also
employs tk as the mutational target.
[0085] The overall mutation rate derived according to the
present inventive assay for HIV-1 was slightly higher and
the tk inactivation rate was slightly lower in comparison to
an in vivo study on Moloney murine leukemia virus
(MoMLV), in which tk was part of a larger mutational
cassette. In the MoMLV study, an overall mutation rate of
1.6x10- 5 /base/cycle and a tk inactivation rate of 3.0% per
kbp were reported. One difference is the types of mutations
observed. The majority of mutations detected in the muta
tional target gene of the present assay were base substitu
tions, while the majority of mutations in the MoMLV study
were labeled as "gross rearrangements" (deletions, deletions
with insertions, duplications, and complex hypermutations).
The majority of gross rearrangements in the MoMLV study
were found at locations corresponding to open regions of
RNA: hairpin loops, internal loops, and bulges. This under
scores the importance of sequence context in interpreting
patterns of mutations. The different patterns of mutation
observed between MoMLV (a y-retrovirus) and HIV-1 (a
lentivirus) also emphasizes the caution that must be exer
cised when extrapolating results from one retroviral genus to
another.

IC2

IC3

IC4

Totals

Number of mutants detected

142

53

154

349

Number of viruses screened

5,265

3,375

7,290

15,930

Mutation frequencya

2.7

1.6

2.1

2.2

2.7

1.6

2.1

2.2

(x10-2 mutations/cycle)
Mutation rateb
5
(X 10-

mutations/base/cycle)

Mutation data for individual Initiator Clones (!C)
aMutation frequency
screened

=

Number of mutants detected/Number of viruses

bMutation rate ~ Mutation frequency/Number of bases in tk gene (996
bases)

[0090]
TABLE 2
Tvoes of mutations observed
No. of mutations observed (%)
Type of mutation a

Present Assay

Mansky Assayb

9 (21)
6 (14)
4 (9)
2 (5)
1 (2)
1 (2)
0
0
1 [ +2 bases] (2)
1 [+ 3 bases] (2)
28 (65)

13
1
0
0
0
1
2
2
0
27

Substitutions

Examplre 6
[0086] The following example illustrates calculation of
the mutation rate.

c~u

*G

___,.A

u~A
c~A
A~G

[0087] Mutation rates were calculated from 27 indepen
dent infections from each IC (FIG. 3 and Table 1). Mock
infections, performed in parallel as a negative control,
showed no colony formation under Hyg+BrdU selection.
The mutation rate was calculated by dividing the mutation
frequency (Table 1) by the size of the tk sequence, which
was 996 bases from start to stop codon. The average
mutation rate for HIV-1 was 2.2x1o-s mutations/base/cycle
of replication (Table 1).
Example 7
[0088] This example illustrates determination of the types
of mutations that resulted in loss of TK function.
[0089] Twenty-seven of 349 mutants were randomly
selected for sequencing in order to determine the types of
mutations that resulted in loss offunction for TK (Table 2).
The majority of mutations (65%) were base substitutions
with a preponderance of c~u (21%) and G~A (14%)
mutations. One G~A and one c~A hypermutant were
observed, as defined by nonconsecutive but repetitive sub
stitution of adenosines. In this case, the hypermutation was
not extensive; only two or three substitutions were observed
in each hypennutant. Insertions were observed approxi
mately twice as often as deletions (23% and 12%, respec
tively). Among the insertions, a predominance of single
adenosine additions was observed at a given time in an
infected individual. Thus, such a hypermutaion could predict
the future pattern of mutation and could assist in making
treatment decisions, especially for newly infected people
and those who are changing drugs due to treatment failure.

G~u
u~G
u~c

G ~ A hypermutantc
C ~ A hypermutantc
Total
Insertions
+A
+G
+U
*Total
Deletions
L\.33
L\.21
L\.11
L\.10
L\.8
L\.5
L\.2

* L\.1

6 (14)

6 (15)

(33)
(3)

(3)
(5)
[+2 bases] (3)
(68)

1 (2)

1 (3)
0

..2...0._

.J..Q2_

10 (23)

2 (5)

0
0
1
1
0
1
1

(2)
(2)
(2)
(2)

_]__@_

1
1
0
0
1
0
0
7

(3)
(3)

(3)

(18)

Total
Deletion with Insertion

5 (12)

10 (25)

M,+15

0

_]_QL_

Total Mutations
Total Mutants Screened

43 (100)
27 [26,892 bases]

40 (100)
38 [10,640 bases]

aThe asterisk indicates statistically significant differences between the
present and Mansky assays, as determined using a one-tailed Fisher's
Exact Test.
bMansky and Temn, 1995.
cEach mutation cmmted separately toward the total number of mutations.
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TABLE 3
Comparison of mutation data between assays
Present Assay

Number of mutants
detected
Number of viruses screened
Mutation frequencyd

Mansky Assay"

15. The cell recited in claim 14 wherein the cell 1s a
dividing cell.
16. The cell recited in claim 14 wherein the cell 1s a
non-dividing cell.
17. An assay for determining a mutation frequency and a
mutation rate of a retrovirus comprising:
a) constructing the vector recited in claim 1;

349
15,930
2.2

8,678c
4.4

b) stably transfecting cells from a cell culture with the
vector from (a)

2.2

3.5

c) placing the cells under selection with a medium select
able for the selectable marker to produce a quantity of
cell clones which contain an integrated vector;

2

(x10- mutations/cycle)
Mutation ratee
5
(X 10-

mutations/base/cycle)

"Mansky and Temin, 1995
blnterpreted from the nwnber of mutant bacterial colonies
crnterpreted from the total number of bacterial colonies
dMutation frequency = Nwnber of mutants detected/Nwnber of viruses
screened
eMutation rate = Mutation frequency/Number of bases in each target
sequence

1. A lentivirus-based retroviral vector wherein the vector

comprises: at least a portion of a lentivirus genome; a
disrupted gag and a disrupted pol gene such that the vector
is rendered replication-defective; a disrupted env gene; and
a mutational cassette, wherein the mutational cassette com
prises sequences encoding: a mutation target promoter
sequence; a genomic source comprising a mutation target
gene wherein there is a number of base pairs in the mutation
target gene; an internal ribosome entry site for expression of
a selectable marker gene; and a selectable marker gene.
2. The vector recited in claim 1 wherein the vector is
transduction- and infection-competent.
3. The vector recited in claim 1 wherein the lentivirus
genome is selected from the group consisting of human
immunodeficiency virus type 1, human immunodeficiency
virus type 2, feline immunodeficiency virus, simian immu
nodeficiency virus, visna-maedi virus, caprine arthritis-en
cephalitis virus, equine infectious anemia virus, bovine
immune deficiency virus, and hybrids thereof.
4. The vector recited in claim 1 wherein the lentivirus
genome comprises human immunodeficiency virus type 1.
5. The vector recited in claim 1 wherein the selectable
marker comprises a positive selectable marker.
6. The vector recited in claim 1 wherein the selectable
marker comprises a hygromycin B resistance gene.
7. The vector recited in claim 1 wherein the selectable
marker comprises a hygromycin B phosphotransferase gene.
8. The vector recited in claim 1 wherein the mutation
target gene comprises greater than 300 base pairs.
9. The vector recited in claim 1 wherein the mutation
target gene comprises greater than 500 base pairs.
10. The vector recited in claim 1 wherein the mutation
target gene comprises greater than 700 base pairs.
11. The vector recited in claim 1 wherein the mutation
target promoter gene comprises a human cytomegalovirus
promoter, and the mutation target comprises a thymidine
kinase gene.
12. The vector recited in claim 1 wherein the genomic
source comprising a mutation target gene comprises a
human herpes virus type 1 gene.
13. A cell comprising the lentivirus-based retroviral vec
tor as recited in claim 1.
14. The cell recited in claim 13 wherein the cell 1s a
dividing or non-dividing eukaryotic cell.

d) transiently transfecting the quantity of cell clones with
a set of helper plasmids to produce a vector virus,
wherein the set of helper plasmids contain a comple
ment of structural genes which permit replication;
e) infecting naive cells from a cell culture with the vector
virus;

f) placing the cells from (e) under selection with the
medium selectable for the selectable marker;
g) cloning the cells from (f) to produce a quantity of
initiator cell clones, wherein each of the quantity of cell
clones is designated as an Initiator Clone (IC);
h) confirming that the mutation target gene is functional
in each IC and sequencing the mutation target gene for
later comparison to mutation target genes which have
undergone a cycle of replication;
i) transiently transfecting the Initiator Clones with a set of
helper plasmids to produce a vector virus;
j) infecting naive cells from a target cell culture with the
vector virus from (i) to produce a quantity of infected
target cells;
k) placing a first portion of the quantity of infected target
cells under selection with the medium selectable for the
selectable marker and a substantially similar second
portion of the quantity of infected target cells under
selection with the medium selectable for the selectable
marker plus a selective medium for the mutation target
gene; wherein a number of drug resistant colonies
grows from the first and second portions, and
I) determining a viral titer for the first portion and a viral
titer for the second portion by counting the number of
drug-resistant colonies;
wherein the mutation frequency is calculated by dividing
the viral titer of the second portion by the viral titer of
the first portion, and the mutation rate is calculated by
dividing the mutation frequency by the number of base
pairs in the mutation target gene.
18. The assay as recited in claim 17 wherein the cell
culture is negative for the selectable marker.
19. The assay as recited in claim 17 wherein the retrovirus
is selected from the group consisting of human immunode
ficiency virus type 1, human immunodeficiency virus type 2,
feline immunodeficiency virus, simian immunodeficiency
virus, visna-maedi virus, caprine arthritis-encephalitis virus,
equine infectious anemia virus, and bovine immune defi
ciency virus, and hybrids thereof.
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20. The assay as recited in claim 17 wherein the retrovirus
is human immunodeficiency virus type 1.
21. The assay as recited in claim 17 wherein the selectable
marker gene comprises a hygromycin B resistance gene and
the medium selectable for the selectable marker comprises
hygromycin B.
22. The assay as recited in claim 21 wherein the hygro
mycin B resistance gene comprises hygromycin B phospho
transferase gene.
23. The assay as recited in claim 17 wherein the mutation
target gene is a thymidine kinase gene and the medium
selectable for the mutation target gene comprises bromode
oxyuridine or HAT.

24. The assay as recited in claim 17 wherein the medium
selectable for the mutation target gene comprises bromode
oxyuridine.
25. The assay as recited in claim 17 wherein the cell
culture comprises 143B cells.
26. The assay as recited in claim 17 wherein the assay
further comprises providing a negative control group,
wherein a quantity of naive cells from the target cell culture
is left uninfected and placed under selection with a medium
selectable for the selectable marker plus a medium select
able for the mutation target gene.

* * * * *

